A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

March 19, 2025

Study Completion Date

June 19, 2025

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

BI 765883

BI 765883

DRUG

gemcitabine

gemcitabine

DRUG

nab-paclitaxel

nab-paclitaxel

Trial Locations (17)

1200

Cliniques Universitaires Saint-Luc, Brussels

3000

UZ Leuven, Leuven

20246

Universitätsklinikum Hamburg, Eppendorf, Hamburg

28034

Hospital Universitario Ramon Y Cajal, Madrid

34232

Florida Cancer Specialists-Sarasota-61670, Sarasota

35042

CTR Eugène Marquis, Rennes

37203

SCRI Oncology Partners, Nashville

69120

Universitätsklinikum Heidelberg, Heidelberg

69373

CTR Leon Berard, Lyon

77030

The University of Texas MD Anderson Cancer Center, Houston

80218

HealthONE, Denver

81377

Klinikum der Universität München AÖR, München

94805

INS Gustave Roussy, Villejuif

06510

Yale Cancer Center, New Haven

277-8577

National Cancer Center Hospital East, Chiba, Kashiwa

104-0045

National Cancer Center Hospital, Tokyo, Chuo-ku

08036

Hospital Clínic de Barcelona, Barcelona

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT06528093 - A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy | Biotech Hunter | Biotech Hunter